Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Oct 13, 2009
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Oncology and hematology patients
- • Life expectancy of minimum of 180 days
- Exclusion Criteria:
- • second or femoral long-term central venous access device
- • known allergy to heparin (HIT)
- • coagulation disorders(INR \>2, Blood platelets \> 1,000,000/mm3)
- • therapeutic intravenous heparin administration
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Vlaams Brabant, Belgium
Patients applied
Trial Officials
Marguerite Stas, MD, PhD
Principal Investigator
Universitaire Ziekenhuizen KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials